NCT02551055View on ClinicalTrials.gov

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 15, 2015

Primary Completion Date

February 17, 2017

Study Completion Date

February 17, 2017

Conditions
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
Interventions
DRUG

MLN1117

MLN1117 Tablets

DRUG

TAK-659

TAK-659 Tablets

DRUG

Alisertib

Alisertib Tablets

DRUG

Paclitaxel

Paclitaxel intravenous infusion

DRUG

Docetaxel

Docetaxel intravenous infusion

Trial Locations (6)

Unknown

Lake Success

New York

Philadelphia

Dallas

Houston

Barcelona

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY